{"protocolSection":{"identificationModule":{"nctId":"NCT00847860","orgStudyIdInfo":{"id":"Neurology-2008-VD"},"organization":{"fullName":"Peking University First Hospital","class":"OTHER"},"briefTitle":"Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions","officialTitle":"Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White","acronym":"CAVAD"},"statusModule":{"statusVerifiedDate":"2009-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-03"},"primaryCompletionDateStruct":{"date":"2011-05","type":"ACTUAL"},"completionDateStruct":{"date":"2011-06","type":"ACTUAL"},"studyFirstSubmitDate":"2009-02-17","studyFirstSubmitQcDate":"2009-02-17","studyFirstPostDateStruct":{"date":"2009-02-19","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-05-05","lastUpdatePostDateStruct":{"date":"2015-05-06","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Yining Huang","oldOrganization":"Peking University First Hospital"},"leadSponsor":{"name":"Peking University First Hospital","class":"OTHER"},"collaborators":[{"name":"Zhejiang Otsuka Pharmaceutical Co., Ltd.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors."},"conditionsModule":{"conditions":["Vascular Dementia","Stroke"],"keywords":["cognition"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":200,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"Cilostazol","interventionNames":["Drug: Cilostazol"]},{"label":"2","type":"ACTIVE_COMPARATOR","description":"Asprin","interventionNames":["Drug: Aspirin"]}],"interventions":[{"type":"DRUG","name":"Cilostazol","description":"Cilostazol 100 mg bid for 12 months","armGroupLabels":["1"]},{"type":"DRUG","name":"Aspirin","description":"Aspirin 100 mg qd for 12 months","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"changes of the scores of MMSE, MOCA,CDR,and Blessed-Roth","timeFrame":"one year"}],"secondaryOutcomes":[{"measure":"stroke recurrence, other vascular ischemic events, bleeding events","timeFrame":"one year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ranging from 40 to 80 years\n2. After newly ischemic stroke from 3 months to 2 years\n3. Brain CT or MRI shows stroke lesions and white matter lesions, ARWMC(Age Related White Matter Change)\\>=4\n4. Moderate or mild cognitive deficits: MMSE 12-26\n5. Vascular or mixed dementia: Hachinski ischemic score\\>4\n6. Moderate or mild disability: MRS\\<=4,NIHSS\\<20\n7. Informed consent\n\nExclusion Criteria:\n\n1. Definitive diagnosis of dementia prior to the stroke\n2. Cerebral hemorrhage in the past\n3. Cerebral embolism result from cardiogenic embolus\n4. Critically ills: MRS\\>4,NIHSS\\>=20\n5. Bed-ridden patient who is hardly discovered newly stroke\n6. patient with sever cardiac, hepatic or nephric complication\n7. dementia caused not by vascular lesions\n8. other diseases disturb the cognitive evaluation\n9. susceptibility to varieties of allergen\n10. abstain from Cilostazol or Asprin\n11. antiplatelet treatment, anticoagulation or fibrinolysis are needed because of other diseases\n12. rejected to participate by the patient or the family","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Huang Yining, MD PhD","affiliation":"Peking University First Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Peking University First Hospital","city":"Beijing","state":"Beijing","zip":"100034","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Shanghai Hua Shan Hospital","city":"Shanghai","state":"Shanghai","zip":"200040","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]},"referencesModule":{"references":[{"pmid":"35833913","type":"DERIVED","citation":"Kwan J, Hafdi M, Chiang LLW, Myint PK, Wong LS, Quinn TJ. Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. Cochrane Database Syst Rev. 2022 Jul 14;7(7):CD012269. doi: 10.1002/14651858.CD012269.pub2."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000003704","term":"Dementia"},{"id":"D000015140","term":"Dementia, Vascular"}],"ancestors":[{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000002537","term":"Intracranial Arteriosclerosis"},{"id":"D000020765","term":"Intracranial Arterial Diseases"},{"id":"D000056784","term":"Leukoencephalopathies"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M6594","name":"Dementia","asFound":"Dementia","relevance":"HIGH"},{"id":"M17551","name":"Dementia, Vascular","asFound":"Vascular Dementia","relevance":"HIGH"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21526","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M5476","name":"Intracranial Arteriosclerosis","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M22211","name":"Intracranial Arterial Diseases","relevance":"LOW"},{"id":"M28281","name":"Leukoencephalopathies","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000077407","term":"Cilostazol"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000001993","term":"Bronchodilator Agents"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018927","term":"Anti-Asthmatic Agents"},{"id":"D000019141","term":"Respiratory System Agents"},{"id":"D000014665","term":"Vasodilator Agents"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000058987","term":"Phosphodiesterase 3 Inhibitors"},{"id":"D000010726","term":"Phosphodiesterase Inhibitors"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M1788","name":"Cilostazol","asFound":"Stored","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M4959","name":"Bronchodilator Agents","relevance":"LOW"},{"id":"M20653","name":"Anti-Asthmatic Agents","relevance":"LOW"},{"id":"M20827","name":"Respiratory System Agents","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M29023","name":"Phosphodiesterase 3 Inhibitors","relevance":"LOW"},{"id":"M13319","name":"Phosphodiesterase Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"Resp","name":"Respiratory System Agents"}]}},"hasResults":false}